{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:36:24Z","timestamp":1791416184183,"version":"4.3.3"},"reference-count":52,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.vaccine.2007.04.086","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T07:45:12Z","timestamp":1179992712000},"page":"5399-5408","source":"Crossref","is-referenced-by-count":135,"title":["The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada"],"prefix":"10.1016","volume":"25","author":[{"given":"Marc","family":"Brisson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"De Wals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Boily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2007.04.086_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"issue":"5","key":"10.1016\/j.vaccine.2007.04.086_bib2","first-page":"1934","article-title":"Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites","volume":"61","author":"Carter","year":"2001","journal-title":"Cancer Res"},{"issue":"31","key":"10.1016\/j.vaccine.2007.04.086_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/oxfordjournals.jncimonographs.a003476","article-title":"Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia","author":"Schiffman","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"31","key":"10.1016\/j.vaccine.2007.04.086_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/oxfordjournals.jncimonographs.a003482","article-title":"Chapter 7: human papillomavirus and cancer of the upper aerodigestive tract","author":"Herrero","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"10","key":"10.1016\/j.vaccine.2007.04.086_bib5","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/JCM.37.10.3316-3322.1999","article-title":"Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients","volume":"37","author":"Brown","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2007.04.086_bib6","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1128\/JCM.33.8.2058-2063.1995","article-title":"Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts","volume":"33","author":"Greer","year":"1995","journal-title":"J Clin Microbiol"},{"issue":"10 (Pt. 1)","key":"10.1016\/j.vaccine.2007.04.086_bib7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/000348949510401002","article-title":"Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis","volume":"104","author":"Pou","year":"1995","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"7","key":"10.1016\/j.vaccine.2007.04.086_bib8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00005537-199707000-00015","article-title":"Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors","volume":"107","author":"Rimell","year":"1997","journal-title":"Laryngoscope"},{"issue":"7","key":"10.1016\/j.vaccine.2007.04.086_bib9","first-page":"1017","article-title":"Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection","volume":"164","author":"Franco","year":"2001","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2007.04.086_bib10","unstructured":"Canadian Cancer Society\/National Cancer Institute of Canada. Canadian Cancer Statistics 2006, ISSN 0835-2976; April 2006 [http:\/\/www.cancer.ca\/vgn\/images\/portal\/cit_86751114\/31\/21\/935505792cw_2006stats_en.pdf.pdf]."},{"issue":"6","key":"10.1016\/j.vaccine.2007.04.086_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2007.04.086_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","article-title":"Human papillomavirus and cervical cancer","volume":"16","author":"Burd","year":"2003","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2007.04.086_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.bjc.6601024","article-title":"Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis","volume":"89","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.vaccine.2007.04.086_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/sti.76.3.162","article-title":"European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts","volume":"76","author":"von Krogh","year":"2000","journal-title":"Sex Transm Infect"},{"issue":"9447","key":"10.1016\/j.vaccine.2007.04.086_bib15","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"9518","key":"10.1016\/j.vaccine.2007.04.086_bib16","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.vaccine.2007.04.086_bib17","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2007.04.086_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2007.04.086_bib19","unstructured":"Health Canada. Drugs and Health Products. Notice of Compliance (NOC). Gardasil. Recombinant human papillomavirus vaccine (Types 6, 11, 16, 18). DIN: 02283190 [accessed March 15, 2007, http:\/\/www.hc-sc.gc.ca\/dhp-mps\/alt_formats\/hpfb-dgpsa\/txt\/prodpharma\/bio2006et.txt]."},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2007.04.086_bib20","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.vaccine.2006.06.014","article-title":"Chapter 13: current findings from prophylactic HPV vaccine trials","volume":"24","author":"Koutsky","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.04.086_bib21","unstructured":"US Food Drug Administration. Center for Biologics Evaluation and Research. Product Approval Information. Licensing Action. GARDASIL. Label. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 9682300; STN: 125126\/0 [accessed March 15, 2007, http:\/\/www.fda.gov\/cber\/products\/hpvmer060806.htm]."},{"issue":"19","key":"10.1016\/j.vaccine.2007.04.086_bib22","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.vaccine.2004.10.029","article-title":"An analytical framework for immunization programs in Canada","volume":"23","author":"Erickson","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.04.086_bib23","unstructured":"National Advisory Committee on Immunization (NACI). Statement on Human Papillomavirus Vaccine. Canada Communicable Disease Report; 2007. p. 33."},{"issue":"5","key":"10.1016\/j.vaccine.2007.04.086_bib24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/0272989X06290485","article-title":"Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs","volume":"26","author":"Brisson","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2007.04.086_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/aje\/kwk059","article-title":"Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty","author":"Van de Velde","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2007.04.086_bib26","unstructured":"Brisson M, Van de Velde N, Boily MC, De Wals P. Estimating the number needed to vaccinate to prevent human papillomavirus related disease and mortality, submitted for publication."},{"issue":"8","key":"10.1016\/j.vaccine.2007.04.086_bib27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2007.04.086_bib28","series-title":"22nd International Papillomavirus Conference","article-title":"Health state transitions following an abnormal Pap smear: implications for health utility assessment in cost-effectiveness analyses","author":"Insinga","year":"2007"},{"issue":"6","key":"10.1016\/j.vaccine.2007.04.086_bib29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.290.6.781","article-title":"Potential health and economic impact of adding a human papillomavirus vaccine to screening programs","volume":"290","author":"Kulasingam","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2007.04.086_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost-effectiveness of a potential vaccine for human papillomavirus","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2007.04.086_bib31","series-title":"Proceedings of the 21st International Papillomavirus Conference","article-title":"Patient preferences for health states related to HPV infection: visual analogue scales versus time trade-off elicitation","author":"Myers","year":"2004"},{"issue":"5","key":"10.1016\/j.vaccine.2007.04.086_bib32","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1086\/427557","article-title":"Development and duration of human papillomavirus lesions, after initial infection","volume":"191","author":"Winer","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2007.04.086_bib33","unstructured":"Statistics Canada. Consumer Price Index [accessed March 15, 2007, http:\/\/www.statcan.ca\/english\/Subjects\/Cpi\/cpi-en.htm]."},{"issue":"3","key":"10.1016\/j.vaccine.2007.04.086_bib34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/01.LGT.0000171665.63976.B2","article-title":"Costs of colposcopy services and their impact on the incidence and mortality rate of cervical cancer in Canada","volume":"9","author":"Benedet","year":"2005","journal-title":"J Low Genit Tract Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2007.04.086_bib35","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.5858\/2003-127-1169-AHPTIT","article-title":"Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation","volume":"127","author":"Lytwyn","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.vaccine.2007.04.086_bib36","unstructured":"The Society of Obstetricians and Gynaecologists of Canada. Human Papillomavirus: the most common sexually transmitted infection [accessed March 15, 2007, http:\/\/www.sogc.org\/health\/pdf\/HPV_e.pdf]."},{"key":"10.1016\/j.vaccine.2007.04.086_bib37","unstructured":"WHO (World Health Organization). Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva, Switzerland; 2001."},{"key":"10.1016\/j.vaccine.2007.04.086_bib38","unstructured":"WHO (World Health Organization). WHO-CHOICE: World Health Organization statistical information system: choosing interventions that are cost effective [4-21-2006, http:\/\/www.who.int\/whosis\/en]."},{"key":"10.1016\/j.vaccine.2007.04.086_bib39","doi-asserted-by":"crossref","unstructured":"Baldwin JR, Brown M, Maynard JP. Insights on the Canadian Economy: interprovincial differences in GDP per capita, labour productivity and work intensity: 1990\u20132003. StatCan Catalogue No. 11-624-MIE-No. 011; 2005.","DOI":"10.2139\/ssrn.1427377"},{"issue":"11","key":"10.1016\/j.vaccine.2007.04.086_bib40","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2007.04.086_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1473-3099(07)70083-X","article-title":"Cost-effectiveness analyses of human papillomavirus vaccination","volume":"7","author":"Newall","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2007.04.086_bib42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2007.04.086_bib43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bjc.6603501","article-title":"Estimating the long-term impact of a prophylactic human papillomavirus 16\/18 vaccine on the burden of cervical cancer in the UK","volume":"96","author":"Kohli","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2007.04.086_bib44","series-title":"23rd International Papillomavirus Conference","article-title":"Psychological impact of cervical screening and condylomas: an epidemiological study (PISCES)","author":"S\u00e9n\u00e9cal","year":"2006"},{"issue":"4","key":"10.1016\/j.vaccine.2007.04.086_bib45","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1185\/030079906X99972","article-title":"Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK","volume":"22","author":"Brown","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.vaccine.2007.04.086_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1363\/3601104","article-title":"The estimated direct medical cost of sexually transmitted diseases among American youth, 2000","volume":"36","author":"Chesson","year":"2004","journal-title":"Perspect Sex Reprod Health"},{"issue":"11","key":"10.1016\/j.vaccine.2007.04.086_bib47","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1086\/375074","article-title":"The health and economic burden of genital warts in a set of private health plans in the United States","volume":"36","author":"Insinga","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2007.04.086_bib48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ajog.2004.01.042","article-title":"The health care costs of cervical human papillomavirus-related disease","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.vaccine.2007.04.086_bib49","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/jnci\/dji162","article-title":"Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy","volume":"97","author":"Kim","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.vaccine.2007.04.086_bib50","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1067\/mob.2003.280","article-title":"A cost-effectiveness analysis of management strategies for cervical intraepithelial neoplasia grades 2 and 3","volume":"188","author":"Kleinberg","year":"2003","journal-title":"Am J Obstet Gynecol"},{"issue":"2 (Pt. 1)","key":"10.1016\/j.vaccine.2007.04.086_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.AOG.0000196500.50044.ce","article-title":"Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests","volume":"107","author":"Kulasingam","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"7533","key":"10.1016\/j.vaccine.2007.04.086_bib52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/bmj.38698.458866.7C","article-title":"Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies","volume":"332","author":"Legood","year":"2006","journal-title":"BMJ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07005270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07005270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T03:18:04Z","timestamp":1628911084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07005270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":52,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0264410X07005270"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.04.086","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}